Jump Trading’s Jazz Pharmaceuticals JAZZ Stock Holding History

Jump Trading’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,100	Closed	-$177K	–	1065
2014 Q3	$177K	Buy	1,100 +200	+22%	+$30.7K	0.01%	652
2014 Q2	$132K	Buy	+900	New	+$125K	0.01%	601

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jump Trading's JAZZ Position: Q4 2018 in Review

Jump Trading sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 1,340 shares — an estimated $225K sold.

Jump Trading first reported a position in JAZZ in Q2 2014 and held it in 3 quarters. The position peaked at $287K in Q3 2014. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

Jump Trading reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Jump Trading sold 1,340 Jazz Pharmaceuticals shares in Q4 2018, an estimated $225K.
Jump Trading first reported a position in Jazz Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Jump Trading's Jazz Pharmaceuticals position peaked at $287K in Q3 2014.
417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Jump Trading's 13F filing for Q4 2018, filed 14 Feb 2019.